Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 expression in pseudomyxoma peritonei.

Zoran Gatalica1, Brian Loggie

  • 1Department of Pathology, Creighton University Medical Center, 601 N 30th Street, Omaha, NE 68131, USA. zgatalica@pathology.creigton.edu

Cancer Letters
|January 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology and Prevention of Lung Cancer in Europe: A Review of Burden, Disparities, and the Path to Equitable Early Detection.

Acta medica academica·2026
Same author

Immunotherapy of endometrial cancer: a review of recent advances.

Immunotherapy·2026
Same author

<i>NTRK1-3</i> fusions in sarcomas: prevalence, significance, and clinical implications - a systematic review.

Future oncology (London, England)·2025
Same author

Glycogen-Rich Clear Cell Carcinoma of the Breast: Report of Two New Cases and an Updated Literature Review.

Acta medica academica·2025
Same author

Acinic Cell Carcinoma of the Breast: A Population-Based Clinicopathologic Study.

Cancer reports (Hoboken, N.J.)·2025
Same author

The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances.

Biomolecules & biomedicine·2025
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same journal

Corrigendum to "Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice" [Cancer Lett. (2022) 31 529 53-69].

Cancer letters·2026
Same journal

Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].

Cancer letters·2026
Same journal

Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers.

Cancer letters·2026
Same journal

Transcriptomic-based molecular classification of ampullary adenocarcinoma.

Cancer letters·2026
See all related articles

Cyclooxygenase-2 (COX-2) is expressed in pseudomyxoma peritonei (PMP). This suggests that COX-2 inhibitors may be a potential treatment option for PMP patients.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pathology

Background:

  • Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucinous ascites.
  • PMP encompasses disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA).
  • Cyclooxygenase-2 (COX-2) is an enzyme implicated in inflammation and tumorigenesis.

Purpose of the Study:

  • To investigate the expression of COX-2 in patients with PMP.
  • To determine if COX-2 expression differs between DPAM and PMCA subtypes.
  • To explore the potential therapeutic implications of COX-2 inhibition in PMP.

Main Methods:

  • Immunohistochemical analysis was performed on tissue samples from 75 PMP patients.
  • Patients were categorized into DPAM (n=25) and PMCA (n=50) groups.

Related Experiment Videos

  • COX-2 expression was evaluated in neoplastic epithelium, stroma, and associated cells.

    • Main Results:

    • COX-2 was expressed in the neoplastic mucinous epithelium of 40% of PMP cases (30/75).
    • Expression rates were similar in both DPAM (10/25, 40%) and PMCA (20/50, 40%) subtypes.
    • Weak COX-2 expression was also observed in non-disseminated appendiceal mucinous neoplasms.

    Conclusions:

    • COX-2 is frequently expressed in PMP, including both DPAM and PMCA.
    • The presence of COX-2 in PMP suggests a potential role for targeted therapy.
    • COX-2 inhibitors may represent a promising therapeutic strategy for patients with PMP.